Biofrontera said the FDA approved its supplemental NDA for Ameluz 10% gel with BF-RhodoLED for superficial basal cell carcinoma, opening a new labeled use and potential sales opportunities.
Biofrontera said the FDA approved its supplemental NDA for Ameluz 10% gel with BF-RhodoLED for superficial basal cell carcinoma. The approval adds a new labeled use and supports commercial rollout.
Follow Biofrontera Inc. (BFRI) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for BFRI